ALLMedicine™ Multiple Myeloma Center

Oct 23rd, 2021 - While there is extensive evidence for genetic variation as a basis for treatment resistance, other sources of variation result from cellular plasticity. Using multiple myeloma as an example of an incurable lymphoid malignancy, we show how cancer c...

Oct 22nd, 2021 - Background: An estimated 79,190 people living in the United States will be diagnosed with lymphoma in 2012, including 9,060 cases of HL, 70,130 cases of non-Hodgkin s lymphoma (NHL) and multiple cases of adult T-cell leukemia/lymphoma. Laboratory ...

Oct 22nd, 2021 - Background: Smoldering multiple myeloma (SMM) is a precursor condition to MM defined by the clinical parameters of M-protein >=3.0 g/dL or bone marrow plasma cells >=10%, and absence of end organ disease. Patients with high-risk SMM have a risk of...

Oct 22nd, 2021 - Carfilzomib is a proteasome inhibitor widely used for the treatment of multiple myeloma. However, cardiac adverse events (CAEs) are a serious side effect of carfilzomib administration. Observational studies based on systematic reviews and real-wor...

Oct 22nd, 2021 - Multiple myeloma is a disease of the older people, whose prognoses are highly heterogeneous. The International Myeloma Working Group (IMWG) proposed a geriatric assessment (GA) based on age, functional status and comorbidities to discriminate betw...

Feb 8th, 2021 - Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.|2021|Dimopoulos MA,Moreau P,Terpos E,Mateos MV,Zweegman S,|diagnosis,epidemiology,therapy,

Dec 6th, 2020 - The bidirectional relationship between cancer and chronic kidney disease (CKD) is complex. Patients with cancer, particularly those with hematological malignancies such as multiple myeloma and lymphoma, are at increased risk of developing acute ki...

Sep 26th, 2020 - Individuals with multiple myeloma (MM) often have reduced functional performance due to the cancer itself or as a direct side effect of cancer treatments. Physical therapy is a part of cancer rehabilitation; however, no guidelines are available to...

Apr 2nd, 2019 - To provide evidence-based recommendations on the treatment of multiple myeloma to practicing physicians and others. ASCO and Cancer Care Ontario convened an Expert Panel of medical oncology, surgery, radiation oncology, and advocacy experts to con...

Feb 7th, 2019 - The novel proteasome inhibitor carfilzomib alone or in combination with other agents is already one of the standard therapies for relapsed and/or refractory multiple myeloma (MM) patients and produces impressive response rates in newly diagnosed M...

Oct 22nd, 2021 - Background: An estimated 79,190 people living in the United States will be diagnosed with lymphoma in 2012, including 9,060 cases of HL, 70,130 cases of non-Hodgkin s lymphoma (NHL) and multiple cases of adult T-cell leukemia/lymphoma. Laboratory ...

Oct 22nd, 2021 - Background: Smoldering multiple myeloma (SMM) is a precursor condition to MM defined by the clinical parameters of M-protein >=3.0 g/dL or bone marrow plasma cells >=10%, and absence of end organ disease. Patients with high-risk SMM have a risk of...

Oct 21st, 2021 - The study duration consists of: An up-to 30-day screening, an up-to 8-day intervention and CD34+ cells apheresis and a follow up for 30 days (+7 days) post last dose of plerixafor, or the initiation of ablative chemotherapy, or the first dose of G...

Oct 21st, 2021 - Background: SMM is a precursor condition to MM defined by the clinical parameters of M-protein >= 3.0 g/dL or bone marrow plasma cells >= 10% and absence of end organ disease. Risk of progression of high risk SMM at 5 years is 72-75% with median t...

Oct 19th, 2021 - Teclistamab is a novel B-cell maturation antigen (BCMA) bispecific antibody that is being evaluated to treat participants with multiple myeloma, an incurable malignant plasma cell disorder. The primary hypothesis of this study is that Tec-Dara wil...

Oct 13th, 2021 - BTK inhibitors, PI3K inhibitors, and CAR T-cell therapies have changed the treatment landscape of many hematologic malignancies, said Harry Paul Erba, MD, PhD, who added that the evolving paradigms underscore the need for individualized decision m...

Oct 6th, 2021 - Krina K. Patel, MD, MSc, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the potential utility of elranatamab (PF-06863135) in multiple myeloma. Elra...

Oct 6th, 2021 - It was 5:00 PM on a Monday, and Andrew Pecora, MD, FACP, CPE, was just wrapping up his practice for the day when one of his nurses came to the door, asking if he could see one more patient. ‘This is a 19-year-old that they just rolled in, and he’...

Oct 6th, 2021 - Andrew A. Lane, MD, PhD SL-401, a novel therapy that targets a cancer stemness pathway, is being investigated in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) in a phase I/II trial that may pave the way for its approval for t...

Oct 6th, 2021 - Richard R. Furman, MD, a member of the Lymphoma/Myeloma Service in the Division of Hematology/Oncology and director of the CLL Research Center at Weill Cornell Medical College, and attending physician at New York-Presbyterian Hospital, discusses t...